☰
Skip to content
Home
Studies
BioFINDER One
BioFINDER Two
BioFINDER Sleep
BioFINDER Preclinical AD
BioFINDER Primary Care
BioFINDER Memory Clinic
Study Group
Publications
News
Deltagare / Participants
Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?
2016
Brain. 2016 Jul 6. pii: aww169.
Palmqvist S
1
,
Mattsson N
1
,
Hansson O
2
.
2024
Individualized, cross-validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms.
2024
Biological mechanisms of resilience to tau pathology in Alzheimer’s disease.
2024
Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease.
2024
Considerations for widespread implementation of blood-based biomarkers of Alzheimer’s disease.
2024
Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease.
2024
Dementia in Down syndrome
2024
Cerebrovascular disease is associated with Alzheimer’s plasma biomarker concentrations in adults with Down syndrome.
2024
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease.
2024
Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions.
2024
Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease.
2024
Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease.
2024
Associations between misfolded alpha-synuclein aggregates and Alzheimer’s disease pathology in vivo.
2024
Proteomic changes in Alzheimer’s disease associated with progressive Aβ plaque and tau tangle pathologies.
2024
The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.
2024
The CentiMarker Project: Standardizing Quantitative Alzheimer’s disease Fluid Biomarkers for Biologic Interpretation